VADUZ, Liechtenstein, Aug. 14, 2024 /PRNewswire/ -- Implantica AG (publ) invites investors to a presentation of the second quarter 2024 at 15:00 CEST on August 21. The interim report for the second quarter will be published at 8:00 a.m. CEST on the same day.
The presentation will be in English via an audiocast with teleconference:
If you wish to participate via webcast, please use the following link:
-- https://ir.financialhearings.com/implantica-q2-report-2024
[https://c212.net/c/link/?t=0&l=en&o=4233123-1&h=459097206&u=https%3A%2F
%2Fir.financialhearings.com%2Fimplantica-q2-report-2024&a=https%3A%2F%2F
ir.financialhearings.com%2Fimplantica-q2-report-2024]
If you wish to participate via teleconference, please register on the link below. After registration, you will be provided the phone number and a conference ID to access the conference.
-- https://conference.financialhearings.com/teleconference/?id=50049902
[https://c212.net/c/link/?t=0&l=en&o=4233123-1&h=4277058473&u=https%3A%2
F%2Fconference.financialhearings.com%2Fteleconference%2F%3Fid%3D50049902
&a=https%3A%2F%2Fconference.financialhearings.com%2Fteleconference%2F%3F
id%3D50049902]
Speakers:
-- CEO Peter Forsell
-- CFO Andreas Öhrnberg
-- Chief Corporate Affairs Officer Nicole Pehrsson
For further information, please contact:
Nicole Pehrsson, Investor Relations
Telephone (CH): +41 (0)79 335 09 49
nicole.pehrsson@implantica.com [mailto:nicole.pehrsson@implantica.com]
Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.
The company's Certified Adviser is FNCA Sweden AB, info@fnca.se [mailto:info@fnca.se]
The information was sent for publication, through the agency of the contact person set out above, on August 14, 2024 at 1:25 p.m. CEST.
About Implantica
Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop((TM)), is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market . Visit www.implantica.com [https://c212.net/c/link/?t=0&l=en&o=4233123-1&h=3153533587&u=http%3A%2F%2Fwww.implantica.com%2F&a=www.implantica.com] for further information.
This information was brought to you by Cision http://news.cision.com [https://c212.net/c/link/?t=0&l=en&o=4233123-1&h=3794512500&u=http%3A%2F%2Fnews.cision.com%2F&a=http%3A%2F%2Fnews.cision.com].
https://news.cision.com/implantica/r/implantica-presents-the-second-quarter-2024-on-august-21-at-15-00-cest,c4024249 [https://c212.net/c/link/?t=0&l=en&o=4233123-1&h=860059908&u=https%3A%2F%2Fnews.cision.com%2Fimplantica%2Fr%2Fimplantica-presents-the-second-quarter-2024-on-august-21-at-15-00-cest%2Cc4024249&a=https%3A%2F%2Fnews.cision.com%2Fimplantica%2Fr%2Fimplantica-presents-the-second-quarter-2024-on-august-21-at-15-00-cest%2Cc4024249]
The following files are available for download:
https://mb.cision.com/Main/19732/4024249/2944750.pdf Implantica presents the second quarter 2024 on August 21 at 15:00 CEST
View original content:https://www.prnewswire.co.uk/news-releases/implantica-presents-the-second-quarter-2024-on-august-21-at-1500-cest-302222305.html [https://www.prnewswire.co.uk/news-releases/implantica-presents-the-second-quarter-2024-on-august-21-at-1500-cest-302222305.html]
Implantica